期刊文献+

T-VAD与T-VD方案治疗多发性骨髓瘤的临床分析 被引量:2

The clinical analysis of multiple myeloma using T-VAD and T-VD regimen
原文传递
导出
摘要 目的:比较T-VAD(长春新碱加阿霉素加地塞米松加沙利度胺)及T-VD(硼替佐米加地塞米松加沙利度胺)方案的疗效及不良反应。方法:回顾74例初治多发性骨髓瘤患者,40例给予T-VAD方案治疗,34例给予T-VD方案治疗,采用t检验的方法进行疗效比较。结果:T-VAD患者中共18例(46%)缓解,T-VD患者中共27例(79%)缓解,两化疗方案差异有统计学意义(P<0.01)。应用T-VAD方案患者中1例(3%)发生深静脉血栓,7例(17%)发生周围神经病变,16例(40%)出现恶心、呕吐、便秘、腹泻等胃肠道反应,9例(22%)发生程度不等的肺部感染,8例(20%)出现血小板减少;应用T-VD方案的患者中2例(6%)发生深静脉血栓,19例(56%)发生周围神经病变,15例(44%)出现消化道反应,18例(53%)发生肺部感染,8例(24%)出现血小板减少。对两种化疗方案的不良反应进行了比较,其中周围神经病变与肺部感染在两组中差异有统计学意义,而深静脉血栓、消化道反应及血小板减少两组差异无统计学意义。结论:T-VD方案缓解率较高,不良反应多,但多数不良反应都较轻微或者可以预防。 Objective:To compare the effect and side-effect in patients with multiple myeloma who were treated with T-VAD regimen and T-VD regimen. Method:To review and analyze 74 newly diagnosed multiple myeloma patients,of whom 40 were given T-VAD and 34 were given T-VD regimen. Result:Out of 40 patients treated with T-VAD regimen,18 patients reached remission and 3 got CR and 15 achieved PR.And out of 34 patients treated with T-VD regimen 27 reached remission and 9 patients achieved CR and 18 reached PR.By T-test analysis,there are significant differences between two groups.The side-effects with T-VAD regimen consisted of deep vein thrombosis(1),peripheral neuropathy(7),gastrointestinal symptoms(16),infection(9),thrombocytopenia(8).And the side-effectsn of T-VD regimen contained deep vein thrombosis(2),peripheral neuropathy(19),gastrointestinal symptoms(15),infection(18),myelosuppression(3),thrombocytopenia(8).Adverse effects of two regimen were compared by t-test,there were significant differences in peripheral neuropathy and lung infection. Conclusion:The T-VD regimen could reach better curative effect even though having more adverse reaction,but most of them could be prevented.
出处 《临床血液学杂志》 CAS 2012年第3期311-313,共3页 Journal of Clinical Hematology
关键词 多发性骨髓瘤 硼替佐米 沙利度胺 multiple myeloma bortezomib thalidomide
  • 相关文献

参考文献9

  • 1中国多发性骨髓瘤诊治指南[J].中华内科杂志,2008,47(10):869-872. 被引量:92
  • 2ZHENG W Y,WEI G Q,YE X J,et al. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience [J]. Leuk Res, 2009,33:1615-1618.
  • 3ZERVAS K, MIHOU D, KATODRITOU E, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma:results of a mul ticenter randomized trial of the Greek myeloma study group[J]. Ann Oncol, 2007,18:1369-1375.
  • 4马肖容,陈银霞,刘捷,张王刚,曹星梅,何爱丽,杨云.不同方案沙利度胺治疗多发性骨髓瘤的临床效果及其与TNF-α水平的关系[J].中国实验血液学杂志,2008,16(6):1312-1315. 被引量:9
  • 5SCHOTS R. Recent advances in myeloma treatment [J]. Transfus Apher Sci,2011,44:223-229.
  • 6UAPRASERT N, VOORHEES P M, MACKMAN N,et al. Venous thromboembolism in multiple myeloma:current perspectives in pathogenesis [J].Eur J Cancer, 2010,46 : 1790-1799.
  • 7CORSO A, MANGIACAVALLI S, VARETTONI M,et al. Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients [J]. Leuk Res, 2010, 34:471-474.
  • 8INFANTE COSSIO P, CABEZAS MACIAN A, P6REZ CEBALLOS J L,et al. Bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma[J]. Med Oral Patol Oral Cir Bucal, 2008,13:E52-E57.
  • 9MATEOS M V. Management of treatment-related ad- verse events in patients with multiple myeloma [J]. Cancer Treat Rev, 2010,6 Suppl 2 : S24-32.

二级参考文献11

  • 1杨云,张王刚,陈银霞,曹星梅,何爱丽,杨惠云,田玮.沙利度胺对人外周血单个核细胞免疫正调控作用[J].中国实验血液学杂志,2006,14(6):1172-1177. 被引量:8
  • 2Singhal S, Methta J, Desikam R,et al. Antitumor activity of thalido-mide in refractory multiple myeloma. N Engl J Med, 1999 ; 341 : 1565 - 1571
  • 3Lonial S. Multiple myeloma: novel approaches for relapsed disease. Clin Lymphoma Myeloma, 2007; 8 (Suppl 1 ) : S18 -23
  • 4Sharma A, Raina V, Uppal G,et al. Long term use of thalidomide: safe and effective. Indian J Cancer, 2007 ; 44 : 108 - 110
  • 5Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma : 10 years later. Blood, 2008 ; 111:3968 - 3977
  • 6Kastritis E, Dimopoulos MA. Thalidomide in the treatment of muhipie myeloma. Best Pract Res Clin Haematol, 2007 ;20:681 -689
  • 7Zervas K, Mihou D, Katodritou E, et al. VAD-doxil versus VADdoxil plus thalidomide as initial treatment for multiple myeloma: results of a muhicenter randomized trial of the Greek Myeloma Study Group. Ann Oneol, 2007 ; 18 : 1369 - 1375
  • 8Tsukagoshi S. Action mechanism of thalidomide in treatment of multiple myeloma. Nippon Rinsho, 2007;65:2291 -2295
  • 9Kast RE. Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of measuring TNF-alpha. Inflammopharmacology, 2006; 14:256-259
  • 10Thompson MA, Witzig TE, Kumar S, et al. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol, 2003 ; 123:305 - 308

共引文献99

同被引文献17

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部